- Abstract
- Core Tip
- Article Highlights
- Full Article with Cover (PDF)
- Full Article (WORD)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (378)
- Timeline of Article Publication (0)
- Authors Evaluation (3)
- Article Quality Tracking (0)
- Reference Citation Analysis (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4023)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 28, 2022 (publication date) through Nov 29, 2023
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Qi Q, Zhong R, Liu YN, Zhao C, Huang Y, Lu Y, Ma Z, Zheng HD, Wu LY. Mechanism of electroacupuncture and herb-partitioned moxibustion on ulcerative colitis animal model: A study based on proteomics. World J Gastroenterol 2022; 28(28): 3644-3665 [PMID: 36161055 DOI: 10.3748/wjg.v28.i28.3644] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i28/3644.htm |
| Number | Citing Articles |
| 1 |
Zheng-Yong Yu, Yu-Sheng Xu, Miao Tang, Wen-Feng Xin. The effect of olsalazine of chinese generic drugs on ulcerative colitis induced by dextran sulfate sodium salt in BALB/c mice. Acta Cirúrgica Brasileira 2023; 38 doi: 10.1590/acb382923
|
| 2 |
Rui-Bin Zhang, Long-Cong Dong, Yuan Shen, Hong-Ying Li, Qin Huang, Shu-Guang Yu, Qiao-Feng Wu. Electroacupuncture alleviates ulcerative colitis by targeting CXCL1: evidence from the transcriptome and validation. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1187574
|